• The Fiix-prothrombin time (Fiix-PT; pronounced 'fix PT') is a new modified prothrombin time sensitive to only factors II and X. It is intended for monitoring oral anticoagulation with vitamin K antagonist but with a possible application to measure other oral anticoagulants.
• A patent for the invention has been granted in the USA and China in 2016 with patent pending status elsewhere.
• The patent is owned by a start-up company, Fiix Diagnostics Ltd (Fiix Greining ehf) founded late in the year 2013. The company is owned by Pall T. Onundarson, Brynja R. Gudmundsdottir, the Landspitali National University Hospital and University of Iceland in Reykjavik, Iceland.
• Fiix is a registered trademark.
• The aim of Fiix Diagnostics Ltd is to fund the patent applications and to provide manufacturing and distribution of the test.

News

July 24 2016:
A meta-analysis published in the International Journal of Laboratory Haematology suggests that monitoring warfarin with Fiix-PT reduces risk of vascular events in NVAF patients at least as much as DOACs.
Compared to traditionally INR monitored warfarin, Fiix-warfarin (warfarin monitored with Fiix-PT) is an improved anticoagulant.

June 7 2016:
A publication in the May 2016 issue of the Journal of Thrombosis and Haemastasis demonstrates that the dilute Fiix prothrombin time may be suitable as a stat test to assess all oral anticoagulants as well as unfractionated and fractionated heparin.